Drugs / BXOS110
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06322394 | Feb 2024 → Mar 2025 | ischemic stroke | Biocells (Beijing) Biotech Co.,Ltd | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07520565 | Jan 2026 → Jul 2027 expected | — | Biocells (Beijing) Biotech Co.,Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BXOS110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07520565 ↗ |
| Route | Intravenous | “Participants received one administration by intravenous infusion.” NCT06322394 ↗ |